Replies to post #10191 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

The January price hike was already baked into Teva’s prior guidance for 2013 Copaxone sales (#msg-81977344), which implies about $2.9B of Copaxone sales in the US.

[indigokid]

Didn't Teva also raise the Copaxone price at the beginning of 2012 by 15% as well?

Now another 10% in 2013. That's about a 100% increase since 2010.

Maybe the silver lining for each year MNTA is delayed in approval-- Teva keeps growing the market via price increases....

Let's hope MNTA's manufacturing process is at least as efficient to allow for 90% margins as well.